Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rapport Therapeutics, Inc. (RAPP : NSDQ)

• Company Description    Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. Number of Employees: 69

• Price / Volume Information    Yesterday's Closing Price: $30.34 Daily Weekly Monthly 20 Day Moving Average: 371,280 shares Shares Outstanding: 47.66 (millions) Market Capitalization: $1,446.04 (millions) Beta: 1.63 52 Week High: $42.27 52 Week Low: $6.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.71% 5.89% 12 Week 13.46% 11.63% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 99 HIGH STREET SUITE 2100 - BOSTON,MA 02110 USA ph: 857-321-8020 fax: - investors@rapportrx.com http://www.rapportrx.com

• General Corporate Information    Officers Abraham N. Ceesay - Chief Executive Officer and Director Steven M. Paul - Chairman and Director Troy Ignelzi - Chief Financial Officer James I. Healy - Director John Maraganore - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75383L102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 47.66 Most Recent Split Date: (:1) Beta: 1.63 Market Capitalization: $1,446.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.75 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.83 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -42.00% vs. Previous Quarter: 5.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -28.60 06/30/25 - -29.99 ROA 12/31/25 - - 09/30/25 - -27.18 06/30/25 - -28.64 Current Ratio 12/31/25 - - 09/30/25 - 36.37 06/30/25 - 22.75 Quick Ratio 12/31/25 - - 09/30/25 - 36.37 06/30/25 - 22.75 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 10.74 06/30/25 - 7.22 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©